id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-285806-363ivs67	Magro, Giuseppe	SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc	2020-05-14		.txt	text/plain	5157	257	41	In a humanized transgenic mouse MERS-CoV infection model, Remdesivir (a drug already being used against SARS-CoV-2 in patients with severe and moderate disease, GS-US-540-5773/4 Studies) showed more activity and efficacy in prophylactic and therapeutic use then the combination of Lopinavir/Ritonavir and Interferon beta 9 , this points towards the necessity to explore other options regarding immune system modulation and how control of viraemia is also essential. More evidence suggests that critically ill patients with severe respiratory failure and SARS-CoV-2 have either immune dysregulation or macrophage-activation syndrome, both of which are characterized by pro-inflammatory cytokines. This is another evidence of the pro-inflammatory role of the trans-signaling pathway and it could also be the explanation as to why some patients show a higher inflammatory response mediated by IL-6, similarly to what is happening with SARS-CoV-2 infection.	./cache/cord-285806-363ivs67.txt	./txt/cord-285806-363ivs67.txt